Targeted and Immune-Based Therapies for Hepatocellular Carcinoma期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

Targeted and Immune-Based Therapies for Hepatocellular Carcinoma

Authors:	Tim F. Greten Chunwei Walter Lai Guangfu Li Kevin F. Staveley-O’Carroll

Affiliation:	1. Thoracic and Gastrointestinal Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland;2. National Cancer Institute CCR Liver Cancer Program, Bethesda, Maryland;3. Liver Disease Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Health, Bethesda, Maryland;4. Department of Surgery, University of Missouri–Columbia, Columbia, Missouri;5. Department of Molecular Microbiology & Immunology, University of Missouri–Columbia, Columbia, Missouri

Abstract:

Keywords:	Tumor Human Checkpoint Inhibitor AFP α-fetoprotein CAR chimeric antigen receptor CELESTIAL Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib CIK cytokine-induced killer CTLA4 cytotoxic T-lymphocyte–associated protein 4 FDA Food and Drug Administration HCC hepatocellular carcinoma IDO indoleamine 2,3-dioxygenase LPS lipopolysaccharide MDSC myeloid-derived suppressor cell NK natural killer PD1 programmed cell death 1 PDL1 programmed death ligand 1 RFA radiofrequency ablation SARAH Sorafenib Versus Radioembolization in Advanced Hepatocellular Carcinoma SHARP Study of Heart and Renal Protection SIRveNIB Selective Internal Radiation Therapy Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma TGFB transforming growth factor β1 TACE transarterial chemoembolization TARE transarterial radio-embolization TCR T-cell receptor Th T-helper TLR4 toll-like receptor 4 Treg T-regulatory VEGFR vascular endothelial growth factor receptor
本文献已被 ScienceDirect 等数据库收录！

设为首页 | 免责声明 | 关于勤云 | 加入收藏